RMDA: The Pharma Growth Engine 💊🚀
The Driver: High-margin growth in chronic treatments.
Revenue hit EGP 3.95B with steady institutional backing. 📈💰
Sharia Status: ✅ Compliant. A stable member of the EGX33 Shariah Index. ☪️📜
The Valuation: Trades at a premium P/E (~21x), reflecting its faster expansion vs. peers. 💎📊
The Technicals:
the 3.79 EGP level (61.8% Fibonacci). This is the last line of defense for the medium-term bullish structure. 📏🛡️
If 3.79 fails, the price is likely headed for a "Mean Reversion" at the 200-day Moving Average (at 3.4). 🧲📉
The Risk: Vulnerable to API import costs and currency-driven margin squeezes. ⚠️🏗️
If you like my posts, please follow and boost 🙌
The Driver: High-margin growth in chronic treatments.
Revenue hit EGP 3.95B with steady institutional backing. 📈💰
Sharia Status: ✅ Compliant. A stable member of the EGX33 Shariah Index. ☪️📜
The Valuation: Trades at a premium P/E (~21x), reflecting its faster expansion vs. peers. 💎📊
The Technicals:
the 3.79 EGP level (61.8% Fibonacci). This is the last line of defense for the medium-term bullish structure. 📏🛡️
If 3.79 fails, the price is likely headed for a "Mean Reversion" at the 200-day Moving Average (at 3.4). 🧲📉
The Risk: Vulnerable to API import costs and currency-driven margin squeezes. ⚠️🏗️
If you like my posts, please follow and boost 🙌
免責事項
これらの情報および投稿は、TradingViewが提供または承認する金融、投資、取引、またはその他の種類の助言もしくは推奨であることを意図したものではなく、またこれらに該当するものでもありません。詳細は利用規約をご覧ください。
免責事項
これらの情報および投稿は、TradingViewが提供または承認する金融、投資、取引、またはその他の種類の助言もしくは推奨であることを意図したものではなく、またこれらに該当するものでもありません。詳細は利用規約をご覧ください。